Delivery Order SPE2DB22D1106-SPE2DB25FFBN8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $8,322.75. This firm fixed price delivery order, which is set to be completed by August 28, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside, competitively awarded contract issued under AmerisourceBergen's existing pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $5,400.47 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $22,154.31 by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Dupixent 300 mg/2 ml pens. This firm fixed price, competitively awarded contract is a non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $110,776.11 for Dupixent 300 mg/2 mL pens on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded procurement supporting federal pharmaceutical supply needs. The contract will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $17,052.18. This is a firm fixed-price delivery order with an ultimate completion date of September 8, 2025, and represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens valued at $9,541.38 under a firm fixed-price contract. This non-set-aside delivery order is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement within DLA's medical supply chain operations. This...
- The Defense Logistics Agency awarded a $66,460.68 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and carries an ultimate completion date of August 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this delivery order, with performance taking place at the company's Conshohocken...
- On August 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $48,364.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This firm fixed-price delivery order, which is not set-aside designated, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The products will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed price delivery order with an ultimate completion date of August 28, 2025, representing a short-term pharmaceutical supply requirement. The contract carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen, headquartered in Conshohocken,...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFBN8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,676.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 5, 2025. This firm fixed-price delivery order, which is a non-set-aside competitive award, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is scheduled for completion on August 6, 2025, and performance will be conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's comprehensive $999.999 billion pharmaceutical supply agreement with DLA Troop Support Medical, which operates through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare systems. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with an extensive range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.7k | 8/5/25 |